logo/base Created with Sketch.
logo echosens
en-us
chevron Contact
English US version chevron
Change region

FibroScan® Expert 630

The complete non-invasive solution for liver disease management.

Powered by LSM by VCTE™, CAP™ and SSM by VCTE™ as part of an overall assessment of the liver.

Ideal point-of-care solution for high-volume hospital-based settings.

chevron chevron
wave

Expand clinical capabilities

The spleen stiffness measurement (SSM by VCTE™) enables risk stratification of patients with advanced chronic liver disease and portal hypertension.1, 2, 3

The embedded ultrasound guidance eases both liver and spleen targeting.

Unique capabilities of SSM by VCTE™

Assess and Monitor Portal Hypertension*
SSM by VCTE™ helps to assess and monitor portal hypertension, the main driver of cirrhosis, in a quick and non-invasive way.

Helps to Assess the Presence of Esophageal Varices*
SSM by VCTE™ can provide added value to help identify high-risk varices and prioritize endoscopies.

Determine Surgery*
SSM by VCTE™ has the potential to triage patients in the general surgical population by assessing portal hypertension, a known risk factor, prior to surgery.

Enhance exam efficiency with improved ergonomics and high-speed processing

FibroScan® Expert 630 offers a high-speed processing, 19-inch touchscreen and a washable touch keyboard.

For the spleen examination with SSM by VCTE™, the M+ probe automatically adjusts to 100 Hz, adapts measurement depth, and adjusts the stiffness range. The ultrasound localization probe is a time-saving technology for easily locating the spleen and liver in complex patients and patients with obesity.

FibroScan® Expert 630 is adapted to all patient morphologies as it can be used with all probes S+, M+ and XL+. The two probe connectors allows to easily switch between probes during exam.

chevron Learn more

User testimonial

quote

Measurements of spleen stiffness using the FibroScan® Expert 630 equipped with the new SSM module may allow identifying esophageal varices with a high risk of bleeding. Additionally, the concomitant measurements of both hepatic and splenic stiffness can distinguish between varices caused by cirrhosis from those due to portal hypertension in the absence of cirrhosis.

Yusuf Yilmaz | Professor and MD. Gastroenterology and Hepatology - Marmara University Hospital, Istanbul, Turkey

chevron Read all testimonials
chevron chevron

Operator perspectives

What our users say about Spleen Stiffness Measurement

chevron Watch the video

FibroScan® Expert 630 comes with a dedicated support

From installation to training and local support, we provide you with the highest quality of services.

chevron Learn more

*SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.

1.Stefanescu H, et al. A novel spleen-dedicated stiffness measurement by FibroScan improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228.
2. Dajti, Elton et al. “A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.” The American journal of gastroenterology vol. 117,11 (2022): 1825-1833. doi:10.14309/ajg.0000000000001887.
3. Baveno VII – R. de Franchis et al. Renewing consensus in portal hypertension. Journal of hepatology vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022.

The FibroScan® Expert 630 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™ ) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available with SmartExam capability.

chevron User Guides FibroScan Expert 630

Extend FibroScan® use

chevron Contact us